Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
Abstract
Objective: To study the effect and safety of entacapone as an adjunct to levodopa treatment in patients with PD with wearing-off motor fluctuations.
Background: Entacapone is a catechol-O-methyltransferase (COMT) inhibitor that has been shown to increase the area under the concentration-time curve of plasma levodopa by decreasing its systemic elimination, thereby promoting and improving therapeutic response to it.
Methods: A total of 171 parkinsonian patients with wearing-off-type motor fluctuations participated in a 6-month randomized, placebo-controlled, double-blind, parallel-group study. The extent of therapeutic response was elicited in the first hand with home diary recordings of "on" and "off" times by the patient and with Unified Parkinson's Disease Rating Scale scoring by the examiner. The patients took either 200 mg entacapone or identical placebos concomitantly with each daily levodopa dose (four to 10 times a day).
Results: Patients' home diaries indicated that entacapone increased the mean (± SD) "on" time significantly (9.3 ± 2.2 to 10.7 ± 2.2 hours; p < 0.01) and correspondingly decreased the "off" time significantly (5.3 ± 2.2 to 4.2 ± 2.2 hours; p < 0.001). The average benefit derived from a daily levodopa dose as related by the patients was increased significantly (p < 0.01). The daily levodopa dose was reduced significantly in the entacapone group, the difference between the groups being 102 mg (p < 0.01). The entacapone-derived increase in the benefit from levodopa was lost almost completely following its withdrawal. Entacapone was well tolerated. Dopaminergic adverse events, which increased, were ameliorated by reducing the levodopa dose. Diarrhea was the most common nondopaminergic adverse event.
Conclusions: Long-term entacapone treatment effectively prolonged the beneficial response to levodopa in parkinsonian patients with the wearing-off phenomenon. The improvement occurred irrespective of the reduction of the levodopa dose.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-178.
2.
Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
3.
Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 1987;22:475-479.
4.
Rinne UK. Treatment of Parkinson's disease: problems with a progressing disease. J Neural Transm 1981;51:161-174.
5.
Kaakkola S, Gordin A, Männistö PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 1994;25:813-824.
6.
Männistö PT. Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994;1:172-179.
7.
Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18]F-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994;44:1292-1297.
8.
Ruottinen HM, Rinne JO, Ruotsalainen UH, et al. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm 1995;10:91-106.
9.
Ishikawa T, Dhawan V, Chaly T, et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 1996;16:854-863.
10.
Bäckström R, Honkanen E, Pippuri A, et al. Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J Med Chem 1989;32:841-846.
11.
Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46:151-157.
12.
Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993;45:419-423.
13.
Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
14.
Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
15.
Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-156.
16.
Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
17.
Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-233.
18.
Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.
19.
Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
20.
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
21.
Kurth MC, Adler CH, St. Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
22.
Myllylä VV, Jackson M, Larsen JP, Baas H for the Tolcapone International Parkinson's Disease Study (TIPS) Group I. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon. A multicentre, double-blind, randomized placebo-controlled trial. Eur J Neurol 1997;4:333-341.
23.
Rajput AH, Martin W, Saint-Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
Information & Authors
Information
Published In
Copyright
© 1998.
Publication History
Published online: November 1, 1998
Published in print: November 1998
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson’s Disease: An Open-Label, Randomized, Crossover Study, Journal of Parkinson's Disease, (1-14), (2023).https://doi.org/10.3233/JPD-230072
- Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes, Neurodegenerative Disease Management, 13, 2, (75-84), (2023).https://doi.org/10.2217/nmt-2022-0038
- Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs, Neuropsychiatric Disease and Treatment, Volume 19, (247-266), (2023).https://doi.org/10.2147/NDT.S273121
- Catechol‐O ‐methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's disease , European Journal of Neurology, 30, S2, (9-14), (2023).https://doi.org/10.1111/ene.15993
- Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease, Expert Opinion on Drug Safety, 22, 7, (563-579), (2023).https://doi.org/10.1080/14740338.2023.2227096
- Small-Molecule Drug Repurposing for Counteracting Phototoxic A2E Aggregation, ACS Chemical Biology, 18, 10, (2170-2175), (2023).https://doi.org/10.1021/acschembio.3c00339
- Structural and Computational Analyses of the Unique Interactions of Opicapone in the Binding Pocket of Catechol O -Methyltransferase: A Crystallographic Study and Fragment Molecular Orbital Analyses , Journal of Chemical Information and Modeling, 63, 14, (4468-4476), (2023).https://doi.org/10.1021/acs.jcim.3c00331
- Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods, Neurology and Therapy, 12, 4, (1033-1049), (2023).https://doi.org/10.1007/s40120-023-00486-5
- Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations, Journal of Neural Transmission, 130, 6, (847-861), (2023).https://doi.org/10.1007/s00702-023-02623-8
- What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?, Expert Opinion on Pharmacotherapy, 23, 10, (1123-1128), (2022).https://doi.org/10.1080/14656566.2022.2060738
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.